Develops gene therapies for inherited retinal diseases and other causes of blindness, including retinitis pigmentosa, Stargardt disease and geographic atrophy.
10-K for FY2025, filed Mar 4, 2026Our technology pipeline includes:View ↗
OCU400- Based on the use of nuclear hormone receptors ("NHRs"), we believe our novel modifier gene therapy platform has the potential to…View ↗
OCU410ST- We initiated dosing in GARDian3 pivotal confirmatory trial for OCU410ST for Stargardt disease ("ST") in July 2025. The OCU410ST…View ↗
OCU410- We completed dosing in Phase 2 of the Phase 1/2 ArMaDa clinical trial for OCU410 for the treatment of geographic atrophy ("GA"), an…View ↗
Ocugen earns collaborative-arrangement revenue from a partner as it carries out work under the arrangement; the amount is tied to its progress, measured against estimated total costs.
10-K for FY2025, filed Mar 4, 2026As described in Notes 2 and 3 to the consolidated financial statements, the Company recorded collaborative arrangement revenue of $4.4…View ↗
$4.4M
10-K for FY2025, filed Mar 4, 2026
$4.4M ↗No. It lost $67.8M in FY2025.
8-K, filed Nov 10, 2026
On November 10, 2026, Ocugen, Inc. (the “Company” or “Ocugen”) entered into an Exclusive License Agreement (the “License Agreement”) with…View ↗
8-K, filed Oct 15, 2026
On October 13, 2026, Ocugen, Inc. (the “Company” or “Ocugen”) entered into an Exclusive License Agreement (the “License Agreement”) with…View ↗
Vaccine programs
The older report included COVAXIN and an inhaled vaccine pipeline alongside gene and cell therapies. The latest report describes the inhaled vaccine platform but no longer lists COVAXIN.
10-K for FY2022, filed Feb 28, 2023Modifier Gene Therapy Platform — Based on the use of nuclear hormone receptors ("NHRs"), we believe our modifier gene therapy platform has…View ↗
We have a Co-Development, Supply and Commercialization Agreement with Bharat Biotech (as amended, the "Covaxin Agreement"), pursuant to…View ↗
In September 2022, we entered into an exclusive license agreement ("WU License Agreement") with The Washington University in St. Louis…View ↗
Emphasis on blindness therapies
The older report presented gene therapies, cell therapy and vaccines as multiple pipeline areas. The latest report centers its overview on modifier gene therapies for retinal diseases and blindness.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 4, 2026Ocugen is aiming to redefine the future of vision through game-changing gene therapies with the potential to address significant, unmet…View ↗
OCU400- Based on the use of nuclear hormone receptors ("NHRs"), we believe our novel modifier gene therapy platform has the potential to…View ↗
Other Programs —View ↗
Loading...